1092 Impact Of MSLT-II on Lymph Node Clearance Surgery in A Tertiary Plastic Surgery Centre

Abstract Aim Cutaneous malignant melanoma is a significant public health challenge in the United Kingdom. Wide local excision with Sentinel Lymph Node Biopsy (SLNB) current standard of treatment for most lesions. Some patients positive SLNB would routinely undergo locoregional Clearance (LNC). Results Multicenter Selective Lymphadenectomy Trial II (MSLT-II) published August 2017 challenged this approach, showing no specific survival benefit, but morbidity associated routine LNC. Our study aims to show change practice at tertiary plastic surgical referral centre response these results. Method We retrospectively reviewed our prospectively maintained database all LNCs performed cutaneous, non-head and neck using search terms ‘clearance’ ‘dissection’ between 2015 2019. 128 axillary groin cutaneous 2015-2019. The range per year varied from 38 10 2019 (mean 25.6, median 28). total number LNCs, as well following decreased after 2017. Conclusions data shows that acknowledged evidence reduced publication MSLT-II. expect avoided has saved resources due length stay, patient’s morbidity, including seromas, infections lymphoedema. recommend skin cancer centres follow order provide excellent care save resources.